1. Home
  2. ELUT vs UNCY Comparison

ELUT vs UNCY Comparison

Compare ELUT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • UNCY
  • Stock Information
  • Founded
  • ELUT 2015
  • UNCY 2016
  • Country
  • ELUT United States
  • UNCY United States
  • Employees
  • ELUT N/A
  • UNCY N/A
  • Industry
  • ELUT Medical Specialities
  • UNCY Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELUT Health Care
  • UNCY Health Care
  • Exchange
  • ELUT Nasdaq
  • UNCY Nasdaq
  • Market Cap
  • ELUT 79.7M
  • UNCY 74.2M
  • IPO Year
  • ELUT 2020
  • UNCY 2021
  • Fundamental
  • Price
  • ELUT $1.13
  • UNCY $4.04
  • Analyst Decision
  • ELUT Strong Buy
  • UNCY Strong Buy
  • Analyst Count
  • ELUT 2
  • UNCY 5
  • Target Price
  • ELUT $7.00
  • UNCY $55.20
  • AVG Volume (30 Days)
  • ELUT 204.9K
  • UNCY 425.0K
  • Earning Date
  • ELUT 11-13-2025
  • UNCY 11-12-2025
  • Dividend Yield
  • ELUT N/A
  • UNCY N/A
  • EPS Growth
  • ELUT N/A
  • UNCY N/A
  • EPS
  • ELUT N/A
  • UNCY N/A
  • Revenue
  • ELUT $23,683,000.00
  • UNCY N/A
  • Revenue This Year
  • ELUT $19.68
  • UNCY N/A
  • Revenue Next Year
  • ELUT $70.28
  • UNCY $4,481.14
  • P/E Ratio
  • ELUT N/A
  • UNCY N/A
  • Revenue Growth
  • ELUT N/A
  • UNCY N/A
  • 52 Week Low
  • ELUT $1.14
  • UNCY $3.40
  • 52 Week High
  • ELUT $5.12
  • UNCY $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 23.21
  • UNCY 41.84
  • Support Level
  • ELUT $1.17
  • UNCY $3.80
  • Resistance Level
  • ELUT $2.38
  • UNCY $4.21
  • Average True Range (ATR)
  • ELUT 0.18
  • UNCY 0.20
  • MACD
  • ELUT -0.10
  • UNCY -0.01
  • Stochastic Oscillator
  • ELUT 0.00
  • UNCY 38.10

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: